Skip to main content

Table 2 Final multivariate generalized estimating equation model (from stepwise model building and comparison process), including adjusted odds ratios of iOAT clients’ likelihood of reporting dissatisfaction with their dose, shown next to unadjusted odds ratios

From: Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)

Block/Step

Variable (and Variable Level)

Bivariate OR (95% CI)

Multivariate AOR (95% CI)

1. Socio-demographics

Agea

0.97 (0.94, 1.01)

0.996 (0.96, 1.03)

Gender (self-identified)

Womanb

Man

0.61 (0.32, 1.16)

0.818 (0.40, 1.66)

First Nations, Métis, or Inuit

Nob

Yes

1.89 (1.00, 3.56)

1.38 (0.67, 2.85)

Education

Some High School or lessb

High School Diploma

1.10 (0.53, 2.27)

1.51 (0.71, 3.22)

≥ Some post-secondary

0.62 (0.31, 1.27)

0.90 (0.43, 1.87)

2. Physical Health

Opiate Treatment Index—Health Section Total Scorec

1.01 (1.00, 1.02)

1.01 (0.99, 1.02)

3. Mental Health

Ever attempted suicide

Nob

Yes

2.29 (1.20, 4.35)

1.39 (0.69, 2.81)

MAP Psychological Score

1.04 (1.01, 1.08)

1.01 (0.98, 1.04)

4. Quality of Life

EQ5D-CAN Score

0.41 (0.11, 1.58)

1.00 (0.22, 4.44)

5. Substance Use and Treatment

Average Daily Prescribed iOAT dosed

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

Days with heroin use in past month

1.02 (1.00, 1.05)

1.00 (0.97, 1.04)

Days with crack cocaine use in past month

0.99 (0.96, 1.02)

1.01 (0.99, 1.04)

FTND: Current smoker

Non-smokerb

Smoker

4.48 (1.66, 12.1)

1.17 (1.06, 1.30)

How troubled client reports feeling about problems associated with criminalized drug use

Untroubledb

Troubled

2.21 (1.21, 4.01)

2.06 (1.12, 3.79)

6. Shared Decision Making

Client rating of doctor involving them in decisions as much as the client wants

Less than excellentb

Excellent

0.65 (0.47, 0.88)

0.81 (0.61, 1.08)

7. Drug Liking

Visual Assessment Scale of "Liking the (prescribed) Drug"

0.98 (0.97, 0.99)

0.98 (0.97, 0.99)

  1. Values are bolded if there is a significant (p < 0.05) difference in means between dose-satisfaction groups (for continuous variables) or significant difference in distribution of dose-satisfaction status between one or more levels of a categorical variable and the (not bolded) reference level
  2. Abbreviations: EQ5D-CAN Canadian version of the EuroQol 5 Dimension descriptive system for health-related quality of life, OTI Opiate Treatment Index, FTND Fagerström Test of Nicotine Dependence, MAP Maudsley Addiction Profile, VAS Visual Assessment Scale
  3. a per 1 year increase
  4. b reference group for both OR and AOR
  5. c (minus Gynecological subscale)
  6. d per 1 mg increase in diacetylmorphine-equivalent-mg